KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M

Gross Profit

$8M68.2% margin

Operating Income

-$31M-253.6% margin

Net Income

-$31M-252.5% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+57.0%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$253M

Total Liabilities

$39M

Stockholders' Equity

$214M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$0	—
Gross Profit	$8M	$0	—
Operating Income	-$31M	-$43M	+29.0%
Net Income	-$31M	-$44M	+30.3%

KNSA Q3 2021 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena